{"filing":{"accession_number":"0001434265-26-000102","cik":"0001434265","ticker":"GNMSF","company_name":"GENMAB A/S","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"gmab_20260715x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434265/000143426526000102/gmab_20260715x6k.htm"},"events":[{"id":18014,"run_id":16168,"accession_number":"0001434265-26-000102","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a company announcement disclosing net sales of DARZALEX for Q2 2026 (USD 4,207 million), which represents a material financial result. Although Genmab receives royalties rather than direct product sales, the announcement of quarterly product sales figures is a standard earnings disclosure that would affect a reasonable investor's assessment of the company's financial performance and royalty revenue stream.","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16695,"accession_number":"0001434265-26-000102","item_number":"EX-99.1","item_title":"gmab_20260715xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a company announcement disclosing net sales of DARZALEX for Q2 2026 (USD 4,207 million), which represents a material financial result. Although Genmab receives royalties rather than direct product sales, the announcement of quarterly product sales figures is a standard earnings disclosure that would affect a reasonable investor's assessment of the company's financial performance and royalty revenue stream.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:23:37.632499+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16695,"accession_number":"0001434265-26-000102","item_number":"EX-99.1","item_title":"gmab_20260715xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a company announcement disclosing net sales of DARZALEX for Q2 2026 (USD 4,207 million), which represents a material financial result. Although Genmab receives royalties rather than direct product sales, the announcement of quarterly product sales figures is a standard earnings disclosure that would affect a reasonable investor's assessment of the company's financial performance and royalty revenue stream.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:23:37.632499+00:00","company_name":"GENMAB A/S","ticker":"GNMSF","filing_date":"2026-07-15"}]}